mitoxantrone - CISMeF

Preferred Label : mitoxantrone;

MeSH definition : An anthracenedione-derived antineoplastic agent.;

MeSH synonym : mitozantrone; dhaq;

CISMeF synonym : 70476-82-3 (Mitoxantrone hydrochloride); AHP brand of mitoxantrone hydrochloride; ASTA medica brand of mitoxantrone hydrochloride; amgen brand of mitoxantrone hydrochloride; baxter oncology brand of mitoxantrone hydrochloride; columbia brand of mitoxantrone hydrochloride; inibsa brand of mitoxantrone hydrochloride; lederle brand of mitoxantrone hydrochloride; wyeth brand of mitoxantrone hydrochloride;

MeSH hyponym : nsc301739; CL-232325; NSC-299195; novantrone; mitroxone; mitoxantrone acetate; pralifan; NSC-301739D; NSC-301739; NSC-287836; mitoxantrone hydrochloride; NSC-279836; onkotrone; NSC 279836; NSC279836; NSC 287836; NSC287836; NSC 299195; NSC299195; NSC 301739; NSC 301739D; NSC301739D; CL 232325; CL232325; Acetate, Mitoxantrone; Hydrochloride, Mitoxantrone; Ralenova; Novantron;

MeSH CAS label : 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-;

MeSH Related Number : mitoxantrone acetate; mitoxantrone hydrochloride; 65271-80-9 (Mitoxantrone); 70476-82-3 (hydrochloride); 70711-41-0 (acetate); U6USW86RD0;

Registry Number MeSH : 65271-80-9;

Related CAS MeSH : 70711-41-0 (Mitoxantrone acetate); U6USW86RD0 (Mitoxantrone hydrochloride);

Wikipedia link : https://en.wikipedia.org/wiki/Mitoxantrone;

Is substance : O;

UNII : BZ114NVM5P;

InChIKey : KKZJGLLVHKMTCM-UHFFFAOYSA-N;

Details

Origin ID

D008942;

UMLS CUI

C0026259;

ATC code(s)
- mitoxantrone [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthraquinone dihydrochloride [Substance BNPC]
Currated CISMeF NLP mapping
- Mitoxantrone [ICD-11 Extension code]
- Mitoxantrone [ICHI extension code]
- Mitoxantrone [SMS substance]
- Mitoxantrone [NCIt concept]
- Mitoxantrone (substance) [SNOMED CT concept]
Pharmacological action(s)
- analgesics [MeSH Descriptor]
- antineoplastic agents [MeSH Descriptor]
- enzyme inhibitors [MeSH Descriptor]
- topoisomerase II inhibitors [MeSH Descriptor]
Record concept(s)
- CL-232325 [MeSH concept]
- NSC-279836 [MeSH concept]
- NSC-287836 [MeSH concept]
- NSC-299195 [MeSH concept]
- NSC-301739 [MeSH concept]
- NSC-301739D [MeSH concept]
- mitoxantrone [MeSH concept]
- mitoxantrone acetate [MeSH concept]
- mitoxantrone hydrochloride [MeSH concept]
- mitroxone [MeSH concept]
- novantrone [MeSH concept]
- onkotrone [MeSH concept]
- pralifan [MeSH concept]
Related MeSH Supplementary Concept(s)
- (mitoxantrone)cerium(IV) [MeSH Supplementary Concept]
- 1,4-dihydroxy-5,8-bis((2-(2-hydroxyethoxy)ethyl)amino)-9,10-anthracenedione [MeSH Supplementary Concept]
- 1-hydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione [MeSH Supplementary Concept]
- 3M protocol [MeSH Supplementary Concept]
- 4-(glycyl-histidyl-lysine)-1,5,8-trihydroxyanthraquinone [MeSH Supplementary Concept]
- 4-(glycyl-histidyl-lysine)-1-hydroxyanthraquinone [MeSH Supplementary Concept]
- 8,11-dihydroxy-4-(2-hydroxyethyl)-6-((2-((2-hydroxyethyl)amino)ethyl)amino)-1,2,3,4,7,12-hexahydronaphtho(2,3-f)quinoxaline-7,12-dione [MeSH Supplementary Concept]
- BBR 2577 [MeSH Supplementary Concept]
- BBR3378 [MeSH Supplementary Concept]
- BEMP protocol [MeSH Supplementary Concept]
- BF-9 protocol [MeSH Supplementary Concept]
- BMVC protocol [MeSH Supplementary Concept]
- CAMP combination [MeSH Supplementary Concept]
- CEMP protocol [MeSH Supplementary Concept]
- CL 232468 [MeSH Supplementary Concept]
- CMC protocol 2 [MeSH Supplementary Concept]
- CMD protocol [MeSH Supplementary Concept]
- CMPP protocol [MeSH Supplementary Concept]
- CMxMF regimen [MeSH Supplementary Concept]
- CN3OP regimen [MeSH Supplementary Concept]
- CNV protocol [MeSH Supplementary Concept]
- DMV regimen [MeSH Supplementary Concept]
- DON protocol [MeSH Supplementary Concept]
- Dexa-PAMB protocol [MeSH Supplementary Concept]
- EORTC GIMEMA AML-10 protocol [MeSH Supplementary Concept]
- EORTC GIMEMA AML-13 protocol [MeSH Supplementary Concept]
- FLAM regimen [MeSH Supplementary Concept]
- FLANG protocol [MeSH Supplementary Concept]
- FMC protocol [MeSH Supplementary Concept]
- FMN regimen [MeSH Supplementary Concept]
- FMP regimen [MeSH Supplementary Concept]
- FND protocol [MeSH Supplementary Concept]
- GEMIA protocol [MeSH Supplementary Concept]
- HD-CNV protocol [MeSH Supplementary Concept]
- LPA97R protocol [MeSH Supplementary Concept]
- M-BNCOD protocol [MeSH Supplementary Concept]
- MAC chemotherapy protocol [MeSH Supplementary Concept]
- MAD protocol [MeSH Supplementary Concept]
- MAV protocol [MeSH Supplementary Concept]
- MB-triple V protocol [MeSH Supplementary Concept]
- MCNO regimen [MeSH Supplementary Concept]
- MCOP protocol [MeSH Supplementary Concept]
- MCP protocol [MeSH Supplementary Concept]
- MEA protocol [MeSH Supplementary Concept]
- MECA protocol [MeSH Supplementary Concept]
- MECP protocol [MeSH Supplementary Concept]
- MEPP protocol [MeSH Supplementary Concept]
- MFL combination [MeSH Supplementary Concept]
- MIFAP regimen [MeSH Supplementary Concept]
- MIMO protocol [MeSH Supplementary Concept]
- MIMOC protocol [MeSH Supplementary Concept]
- MINE protocol [MeSH Supplementary Concept]
- MINE-BOP protocol [MeSH Supplementary Concept]
- MINE-ESHAP protocol [MeSH Supplementary Concept]
- MINT protocol [MeSH Supplementary Concept]
- MITT protocol [MeSH Supplementary Concept]
- MLL-93 protocol [MeSH Supplementary Concept]
- MMIP protocol [MeSH Supplementary Concept]
- MMM protocol 2 [MeSH Supplementary Concept]
- MNCOP-B protocol [MeSH Supplementary Concept]
- MOD protocol [MeSH Supplementary Concept]
- MRC AML 10 protocol [MeSH Supplementary Concept]
- MV2 protocol [MeSH Supplementary Concept]
- MVC protocol 2 [MeSH Supplementary Concept]
- MVF protocol [MeSH Supplementary Concept]
- MVLP protocol [MeSH Supplementary Concept]
- MVMJ protocol [MeSH Supplementary Concept]
- MVPP-Bleo protocol [MeSH Supplementary Concept]
- MVT protocol [MeSH Supplementary Concept]
- MiCMA protocol [MeSH Supplementary Concept]
- MiCaT protocol [MeSH Supplementary Concept]
- NCVB protocol [MeSH Supplementary Concept]
- NEO-MACOP-B protocol [MeSH Supplementary Concept]
- NMF protocol [MeSH Supplementary Concept]
- NOAC protocol [MeSH Supplementary Concept]
- NOP protocol [MeSH Supplementary Concept]
- NOP-bolus regimen [MeSH Supplementary Concept]
- NOPE protocol [MeSH Supplementary Concept]
- NOPP protocol [MeSH Supplementary Concept]
- NOVP protocol [MeSH Supplementary Concept]
- O,O'-bis-(3'-iodopropyl)-1,4-dihydroxyanthraquinone [MeSH Supplementary Concept]
- OPEN protocol [MeSH Supplementary Concept]
- P-COMM-B protocol [MeSH Supplementary Concept]
- PAME protocol [MeSH Supplementary Concept]
- PEN protocol [MeSH Supplementary Concept]
- PMitCEBO protocol [MeSH Supplementary Concept]
- PNMF protocol [MeSH Supplementary Concept]
- POEM-Bleo protocol [MeSH Supplementary Concept]
- PmM protocol [MeSH Supplementary Concept]
- R-FCM protocol [MeSH Supplementary Concept]
- RIME regimen [MeSH Supplementary Concept]
- T-NOP protocol [MeSH Supplementary Concept]
- TAM protocol [MeSH Supplementary Concept]
- TEMP protocol [MeSH Supplementary Concept]
- TMJ protocol [MeSH Supplementary Concept]
- TMM protocol [MeSH Supplementary Concept]
- TNT protocol [MeSH Supplementary Concept]
- VEPEMB protocol [MeSH Supplementary Concept]
- VIM-D protocol [MeSH Supplementary Concept]
- VIM3-ARA C regimen [MeSH Supplementary Concept]
- VIMB protocol [MeSH Supplementary Concept]
- VMD protocol [MeSH Supplementary Concept]
- VMMc protocol [MeSH Supplementary Concept]
- VMP regimen [MeSH Supplementary Concept]
- VNCOP-B protocol [MeSH Supplementary Concept]
- WRC 213 [MeSH Supplementary Concept]
- ametantrone [MeSH Supplementary Concept]
- aminatrone 1 [MeSH Supplementary Concept]
- cyclone protocol [MeSH Supplementary Concept]
- mitoxantrone 4'-beta-D-glucoside [MeSH Supplementary Concept]
- mitoxantrone carboxylic acid [MeSH Supplementary Concept]
- mitoxantrone dicarboxylic acid [MeSH Supplementary Concept]
- mitoxantrone-copper(II) [MeSH Supplementary Concept]
- mitoxantrone-tetrachloroplatinum dianion complex [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Mitoxantrone [ICD-11 Extension code]
- Mitoxantrone [NCIt concept]
- Mitoxantrone (substance) [SNOMED CT concept]
- Product containing mitoxantrone (medicinal product) [SNOMED CT concept]
- mitoxantrone [ATC Code]
Validated automatic mappings to BTNT
- 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthraquinone dihydrochloride [Substance BNPC]
- Mitoxantrone Hydrochloride [NCIt concept]
- Mitoxantrone hydrochloride [SMS substance]
- Mitoxantrone hydrochloride (substance) [SNOMED CT concept]
- mitoxantrone [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients